Literature DB >> 12076379

Corticosteroids for acute ischaemic stroke.

N Qizilbash1, S L Lewington, J M Lopez-Arrieta.   

Abstract

BACKGROUND: Much of the brain swelling in ischaemic stroke is due to cytotoxic oedema, which is related to cell membrane dysfunction. Early treatment with corticosteroids may help reduce the swelling and improve the outcomes after a stroke.
OBJECTIVES: The objective of this review was to assess the effect of corticosteroids in acute presumed ischaemic stroke. SEARCH STRATEGY: We searched the Cochrane Stroke Group trials register (last searched: 10 April 2001) and contacted investigators in the field. SELECTION CRITERIA: Published randomised trials comparing corticosteroids with placebo or control in people with acute (presumed or definite) ischaemic stroke. Trials were included if treatment began within 48 hours of stroke onset and if clinical outcome was assessed. DATA COLLECTION AND ANALYSIS: Two reviewers independently applied the inclusion criteria, assessed trial quality and extracted the data. MAIN
RESULTS: Seven trials involving 453 people were included. Details of trial quality that may relate to bias were not available from most trials. No difference was shown in the odds of death within one year (odds ratio 1.08, 95% confidence interval 0.68 to 1.72). Treatment did not appear to improve functional outcome in survivors. Six trials reported neurological impairment but pooling the data was impossible because no common scale or time interval was used. The results were inconsistent between individual trials. The only adverse effects reported were small numbers of gastrointestinal bleeds, infections and deterioration of hyperglycaemia across both groups. Results unchanged since last update. REVIEWER'S
CONCLUSIONS: There is not enough evidence to evaluate corticosteroid treatment for people with acute presumed ischaemic stroke. Conclusions unchanged since last update.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12076379     DOI: 10.1002/14651858.CD000064

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  18 in total

1.  [Recommendations of the European Stroke Initiative (EUSI) for treatment of ischemic stroke--update 2003. I. organization and acute therapy].

Authors:  Sonja Külkens; Peter Arthur Ringleb; Werner Hacke
Journal:  Nervenarzt       Date:  2004-04       Impact factor: 1.214

2.  Non-arteritic anterior ischemic optic neuropathy versus cerebral ischemic stroke.

Authors:  Sohan Singh Hayreh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-04-21       Impact factor: 3.117

Review 3.  Predicting outcome after childhood brain injury.

Authors:  Rob Forsyth; Fenella Kirkham
Journal:  CMAJ       Date:  2012-06-18       Impact factor: 8.262

4.  Managing malignant cerebral infarction.

Authors:  J Marc Simard; Juan Sahuquillo; Kevin N Sheth; Kristopher T Kahle; Brian P Walcott
Journal:  Curr Treat Options Neurol       Date:  2011-04       Impact factor: 3.598

Review 5.  Microglial activation in stroke: therapeutic targets.

Authors:  Midori A Yenari; Tiina M Kauppinen; Raymond A Swanson
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

6.  Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood-brain barrier.

Authors:  Carola Förster; Malgorzata Burek; Ignacio A Romero; Babette Weksler; Pierre-Olivier Couraud; Detlev Drenckhahn
Journal:  J Physiol       Date:  2008-02-07       Impact factor: 5.182

7.  [European Stroke Organisation 2008 guidelines for managing acute cerebral infarction or transient ischemic attack : part 2].

Authors:  P D Schellinger; P Ringleb; W Hacke
Journal:  Nervenarzt       Date:  2008-10       Impact factor: 1.214

8.  Occludin as direct target for glucocorticoid-induced improvement of blood-brain barrier properties in a murine in vitro system.

Authors:  Carola Förster; Christine Silwedel; Nikola Golenhofen; Malgorzata Burek; Silke Kietz; Joachim Mankertz; Detlev Drenckhahn
Journal:  J Physiol       Date:  2005-03-24       Impact factor: 5.182

9.  Deficiency of vasodilator-stimulated phosphoprotein (VASP) increases blood-brain-barrier damage and edema formation after ischemic stroke in mice.

Authors:  Peter Kraft; Peter Michael Benz; Madeleine Austinat; Marc Elmar Brede; Kai Schuh; Ulrich Walter; Guido Stoll; Christoph Kleinschnitz
Journal:  PLoS One       Date:  2010-12-03       Impact factor: 3.240

10.  Pharmacologic management of brain edema.

Authors:  Alexander Papangelou; John J Lewin; Marek A Mirski; Robert D Stevens
Journal:  Curr Treat Options Neurol       Date:  2009-01       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.